Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on ...
COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced the publication of an …